<DOC>
	<DOCNO>NCT02644369</DOCNO>
	<brief_summary>This phase 2 study whose main purpose evaluate gene change immune biomarkers patient solid tumor treatment pembrolizumab relation response treatment . Pembrolizumab monoclonal antibody design block protein call program cell death 1 ligand 1 ( PD-L1 ) allow body 's immune system kill cancer cell .</brief_summary>
	<brief_title>Study Effects Pembrolizumab Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This study involve treatment pembrolizumab , test procedure do safety , collection archival tumor tissue , fresh tumor biopsy , blood sample biomarker research ( include genetic testing ) .</detailed_description>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Squamous Cell</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Be willing able provide write informed consent/assent trial . Be 18 year age old day signing inform consent . Have histologically cytologicallydocumented , locallyadvanced , metastatic solid malignancy incurable either ( ) fail prior standard therapy , ( b ) standard therapy exist , ( c ) standard therapy consider appropriate patient treat physician . There limit number prior treatment regimen . Have one follow advanced ( unresectable and/or metastatic ) solid tumor indication : Squamous cell cancer head neck Triple negative breast cancer Epithelial ovarian cancer Malignant melanoma Advanced solid tumor Have measurable disease base Response Evaluation Criteria In Solid Tumors ( RECIST ) 1.1 . Be willing provide tissue newly obtain core excisional biopsy tumor lesion . Patients newlyobtained sample provide ( e.g . inaccessible patient safety concern ) eligible study . Have performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . Demonstrate adequate organ function . Negative pregnancy test female patient childbearing potential . Must use approve method birth control course study 120 day last dose study drug . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigational device within 4 week first dose treatment . Has diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior first dose trial treatment . Has know history active TB ( Bacillus Tuberculosis ) . Hypersensitivity pembrolizumab excipients . Has prior anticancer monoclonal antibody ( mAb ) within 4 week prior study Day 1 recover adverse event due agent administer 4 week earlier . Has prior chemotherapy , target small molecule therapy , radiation therapy within 2 week prior Study Day 1 recover adverse event due previously administer agent . Has know additional malignancy progress require active treatment . Has know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Has active autoimmune disease require systemic treatment past 2 year Has know history , evidence active , noninfectious pneumonitis . Has active infection require systemic therapy . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere patient 's participation full duration trial , best interest patient participate , opinion treat investigator . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . Is pregnant breastfeeding , expect conceive father child within project duration trial , start screen visit 120 day last dose trial treatment . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 agent . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) . Has receive live vaccine within 30 day plan start study therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>